Julia Dittrich1, Frank Beutner2, Andrej Teren2, Joachim Thiery1, Ralph Burkhardt1, Markus Scholz3, Uta Ceglarek4. 1. LIFE -Leipzig Research Center for Civilization Diseases, Leipzig University, Philipp-Rosenthal-Strasse 27, 04103 Leipzig, Germany; Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Paul-List-Strasse 13-15, 04103 Leipzig, Germany. 2. LIFE -Leipzig Research Center for Civilization Diseases, Leipzig University, Philipp-Rosenthal-Strasse 27, 04103 Leipzig, Germany; Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Paul-List-Strasse 13-15, 04103 Leipzig, Germany; Department of Internal Medicine / Cardiology, University of Leipzig Heart Center, Struempellstrasse 39, 04289 Leipzig, Germany. 3. LIFE -Leipzig Research Center for Civilization Diseases, Leipzig University, Philipp-Rosenthal-Strasse 27, 04103 Leipzig, Germany; Institute for Medical Informatics, Statistics and Epidemiology, Leipzig University, Haertelstrasse 16-18, 04107 Leipzig, Germany. 4. LIFE -Leipzig Research Center for Civilization Diseases, Leipzig University, Philipp-Rosenthal-Strasse 27, 04103 Leipzig, Germany; Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Paul-List-Strasse 13-15, 04103 Leipzig, Germany. Electronic address: uta.ceglarek@medizin.uni-leipzig.de.
Abstract
BACKGROUND AND AIMS: Dyslipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). As key regulators of lipoprotein metabolism, apolipoproteins (apos) are discussed as vascular risk factors. This study aimed to analyze associations of major plasma apos with coronary artery disease (CAD), peripheral artery disease (PAD) and carotid artery plaque (CAP) to elucidate their diagnostic potential in risk assessment. METHODS: ApoA-I, apoA-II, apoA-IV, apoB-100, apoC-I, apoC-III, apoE, and apoJ were simultaneously quantified in 3 μL EDTA-plasma by LC-MS/MS in a case-control subgroup of the Leipziger LIFE-Heart Study (N = 911). Confounder analysis with demographic, clinical covariates and serum lipids, cardiac, inflammatory, and hepatic markers were performed. Apos were associated with CAD, CAP, and PAD in a multivariate regression model. RESULTS: Fasting and statin therapy showed strongest effects on apo concentrations. Inverse correlations of HDL-related apos A-I, A-II, A-IV, and C-I were observed for troponin T and interleukin 6. Concentrations of apos A-II, B-100, C-I, and E were decreased under statin therapy. After adjustment for influencing factors and related lipids, only apoB-100 (odds ratio per one SD [OR], 1.39; 95% confidence interval [CI], 1.05-1.84) was independently associated with CAD while apoA-IV (OR, 0.74; 95% CI 0.58-0.95) indicated PAD. ApoB-100 (OR, 1.55; 95% CI, 1.18-2.04), apoC-III (OR, 1.30; 95% CI, 1.06-1.58), and apoE (OR, 1.34; 95% CI, 1.13-1.58) were associated with CAP. CONCLUSIONS: Triglyceride rich lipoproteins (TRLs) associated apos A-IV, B-100, C-III, and E are independently associated with stable ASCVD, providing further evidence for a potential role of TRLs in atherogenesis.
BACKGROUND AND AIMS: Dyslipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). As key regulators of lipoprotein metabolism, apolipoproteins (apos) are discussed as vascular risk factors. This study aimed to analyze associations of major plasma apos with coronary artery disease (CAD), peripheral artery disease (PAD) and carotid artery plaque (CAP) to elucidate their diagnostic potential in risk assessment. METHODS:ApoA-I, apoA-II, apoA-IV, apoB-100, apoC-I, apoC-III, apoE, and apoJ were simultaneously quantified in 3 μL EDTA-plasma by LC-MS/MS in a case-control subgroup of the Leipziger LIFE-Heart Study (N = 911). Confounder analysis with demographic, clinical covariates and serum lipids, cardiac, inflammatory, and hepatic markers were performed. Apos were associated with CAD, CAP, and PAD in a multivariate regression model. RESULTS: Fasting and statin therapy showed strongest effects on apo concentrations. Inverse correlations of HDL-related apos A-I, A-II, A-IV, and C-I were observed for troponin T and interleukin 6. Concentrations of apos A-II, B-100, C-I, and E were decreased under statin therapy. After adjustment for influencing factors and related lipids, only apoB-100 (odds ratio per one SD [OR], 1.39; 95% confidence interval [CI], 1.05-1.84) was independently associated with CAD while apoA-IV (OR, 0.74; 95% CI 0.58-0.95) indicated PAD. ApoB-100 (OR, 1.55; 95% CI, 1.18-2.04), apoC-III (OR, 1.30; 95% CI, 1.06-1.58), and apoE (OR, 1.34; 95% CI, 1.13-1.58) were associated with CAP. CONCLUSIONS: Triglyceride rich lipoproteins (TRLs) associated apos A-IV, B-100, C-III, and E are independently associated with stable ASCVD, providing further evidence for a potential role of TRLs in atherogenesis.
Authors: Janne Pott; Jesper R Gådin; Elizabeth Theusch; Marcus E Kleber; Graciela E Delgado; Holger Kirsten; Stefanie M Hauck; Ralph Burkhardt; Hubert Scharnagl; Ronald M Krauss; Markus Loeffler; Winfried März; Joachim Thiery; Angela Silveira; Ferdinand M Van't Hooft; Markus Scholz Journal: Hum Mol Genet Date: 2022-03-21 Impact factor: 6.150
Authors: Mathias Cardner; Mustafa Yalcinkaya; Sandra Goetze; Edlira Luca; Miroslav Balaz; Monika Hunjadi; Johannes Hartung; Andrej Shemet; Nicolle Kränkel; Silvija Radosavljevic; Michaela Keel; Alaa Othman; Gergely Karsai; Thorsten Hornemann; Manfred Claassen; Gerhard Liebisch; Erick Carreira; Andreas Ritsch; Ulf Landmesser; Jan Krützfeldt; Christian Wolfrum; Bernd Wollscheid; Niko Beerenwinkel; Lucia Rohrer; Arnold von Eckardstein Journal: JCI Insight Date: 2020-01-16
Authors: Lars Lind; Bruna Gigante; Yan Borné; Tobias Feldreich; Jerzy Leppert; Pär Hedberg; Carl Johan Östgren; Fredrik H Nyström; Johan Sundström; Johan Ärnlöv; Damiano Baldassarre; Elena Tremoli; Fabrizio Veglia; Anders Hamsten; Christopher J O'Donnell; Nora Franceschini; Marju Orho-Melander; Jan Nilsson; Olle Melander; Gunnar Engström; Anders Mälarstig Journal: Arterioscler Thromb Vasc Biol Date: 2021-03-04 Impact factor: 8.311
Authors: Julius L Katzmann; Christian M Werner; Tatjana Stojakovic; Winfried März; Hubert Scharnagl; Ulrich Laufs Journal: Lipids Health Dis Date: 2020-05-30 Impact factor: 3.876